CSBR — Champions Oncology Income Statement
0.000.00%
- $89.83m
- $80.26m
- $56.94m
- 80
- 57
- 73
- 80
Annual income statement for Champions Oncology, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 41 | 49.1 | 53.9 | 50.2 | 56.9 |
Cost of Revenue | |||||
Gross Profit | 19.6 | 25.5 | 24.3 | 20.8 | 28.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 40.7 | 48.5 | 59.1 | 57.5 | 52.4 |
Operating Profit | 0.366 | 0.607 | -5.26 | -7.36 | 4.55 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.437 | 0.583 | -5.27 | -7.31 | 4.63 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.362 | 0.548 | -5.33 | -7.28 | 4.7 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.362 | 0.548 | -5.33 | -7.28 | 4.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.362 | 0.548 | -5.33 | -7.28 | 4.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.021 | 0.034 | -0.355 | -0.516 | 0.343 |